Kostas Biliouris
Stock Analyst at Oppenheimer
(1.27)
# 3,461
Out of 4,382 analysts
450
Total ratings
38.8%
Success rate
-0.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics | Reiterated: Buy | $23 | $6.37 | +261.07% | 4 | Jun 3, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $75 | $32.62 | +129.92% | 58 | Jun 1, 2026 | |
| EVMN Evommune | Reiterated: Buy | $50 | $19.92 | +151.00% | 3 | May 15, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.06 | +259.48% | 18 | May 12, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $37 | $15.75 | +134.92% | 37 | May 7, 2026 | |
| DSGN Design Therapeutics | Reiterated: Buy | $18 → $21 | $10.65 | +97.18% | 3 | May 4, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $500 | $303.05 | +64.99% | 37 | May 1, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Reiterated: Buy | $55.74 | $8.20 | +579.73% | 2 | Apr 20, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $9 | $1.50 | +500.00% | 2 | Apr 9, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $4.03 | +148.14% | 1 | Apr 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.41 | +963.83% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $10.72 | +105.22% | 18 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $62 | $39.62 | +56.49% | 32 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $56.77 | - | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $74.48 | - | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.75 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.54 | - | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.50 | - | 20 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $67.61 | - | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $29.40 | - | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.4927 | - | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.04 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.17 | - | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.64 | - | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.29 | - | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $51.84 | +44.68% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.01 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $237.00 | n/a | 1 | Jun 16, 2022 |
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $23
Current: $6.37
Upside: +261.07%
Legend Biotech
Jun 1, 2026
Reiterated: Buy
Price Target: $75
Current: $32.62
Upside: +129.92%
Evommune
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $19.92
Upside: +151.00%
Prime Medicine
May 12, 2026
Reiterated: Buy
Price Target: $11
Current: $3.06
Upside: +259.48%
Sarepta Therapeutics
May 7, 2026
Reiterated: Buy
Price Target: $37
Current: $15.75
Upside: +134.92%
Design Therapeutics
May 4, 2026
Reiterated: Buy
Price Target: $18 → $21
Current: $10.65
Upside: +97.18%
Alnylam Pharmaceuticals
May 1, 2026
Reiterated: Buy
Price Target: $500
Current: $303.05
Upside: +64.99%
Satellos Bioscience Inc.
Apr 20, 2026
Reiterated: Buy
Price Target: $55.74
Current: $8.20
Upside: +579.73%
ProQR Therapeutics
Apr 9, 2026
Reiterated: Buy
Price Target: $9
Current: $1.50
Upside: +500.00%
Opus Genetics
Apr 7, 2026
Reiterated: Buy
Price Target: $10
Current: $4.03
Upside: +148.14%
Mar 31, 2026
Reiterated: Buy
Price Target: $15
Current: $1.41
Upside: +963.83%
Mar 13, 2026
Reiterated: Buy
Price Target: $22
Current: $10.72
Upside: +105.22%
Jan 15, 2026
Maintained: Buy
Price Target: $62
Current: $39.62
Upside: +56.49%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $56.77
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $74.48
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $2.75
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $13.54
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $6.50
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $67.61
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $29.40
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.4927
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $17.04
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $6.17
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $8.64
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: -
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $51.84
Upside: +44.68%
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $7.01
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $237.00
Upside: n/a